Centessa Pharmaceuticals announced that it has commenced an underwritten public offering of $100M of American Depositary Shares, each representing one ordinary share. All of the ADSs are being offered by Centessa. Goldman Sachs and Leerink Partners are acting as lead joint book-running managers for the proposed offering. Evercore ISI, Guggenheim Securities and BMO Capital Markets are also acting as joint book-running managers for the proposed offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa Pharmaceuticals Advances Narcolepsy Drug Trials
- Centessa announces open IND for ORX750
- Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
- Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
- Centessa reports Q4 EPS (38c), consensus (48c)
